Mirvie has announced new research demonstrating its RNA platform’s ability to predict severe fetal growth restriction months before delivery. The findings, presented at the Society for Maternal-Fetal Medicine annual meeting, show the platform can identify 60% of at-risk cases through a simple maternal blood test.

The research analyzed more than 5,000 geographically and demographically diverse pregnancies, representing the largest molecular study of pregnancy to date. The platform identified a unique RNA signature for severe growth restriction that is independent of other conditions like preeclampsia, chronic hypertension, and gestational diabetes.

“There’s a large unmet need to better identify babies most at risk for stillbirth and other negative outcomes as indicated by poor growth because the majority are undiagnosed before birth,” said Dr. Kara Rood, Clinical Associate Professor of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center and principal investigator of the study. “Approximately 70% of babies with severe growth restriction – characterized as babies in the <third percentile for growth and at highest risk for stillbirth – are missed by a standard ultrasound. This leads to overtreatment and extra monitoring for those who don’t need it and insufficient monitoring and intervention for those who do.”

“Similar to the breakthroughs that propelled the molecular understanding of breast cancer in the 1990s, obstetrics can now move towards a new standard of care based on the molecular characteristics of each pregnancy,” said Maneesh Jain, CEO and co-founder of Mirvie. “With the Mirvie RNA Platform, we can move toward a proactive and personalized care approach in maternal health that focuses on preventing serious pregnancy complications.”

The findings add to Mirvie’s previous research on predicting preeclampsia and preterm birth risk, published in Nature and the American Journal of Obstetrics and Gynecology respectively. The company’s RNA platform examines over 20,000 RNA transcripts per patient and has analyzed data from nearly 11,000 pregnancies across the United States.

Show CommentsClose Comments

Leave a comment